Immatics IMTX
NASDAQ IMTX
$9.56 +0.10 (+1.06%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immatics (IMTX) Cash from Investing Activities (2019 - 2026)

Immatics (IMTX) posted Cash from Investing Activities of -$33.7 million for Q4 2025, down 123.48% sequentially from $143.4 million in Q3 2025, and up 33.55% YoY from -$25.2 million in Q4 2024.

Analysis

Immatics (IMTX) Cash from Investing Activities (2019 - 2026) Analysis & Trends

Immatics has reported Cash from Investing Activities for 7 years, with the latest figure at -$33.7 million in Q4 2025.

  • Quarterly Cash from Investing Activities rose 33.55% year-over-year to -$33.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $231.7 million (up 240.78% YoY) and the FY2025 annual result came in at $231.4 million, up 240.28% from the prior year.
  • Cash from Investing Activities retreated to -$33.7 million in Q4 2025 per IMTX's latest filing, from $143.4 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $143.4 million in Q3 2025 and troughed at -$262.7 million in Q1 2024.
  • A 5-year average of -$8.7 million and a median of -$3.0 million in 2023 frame the typical range for Cash from Investing Activities.
  • The widest YoY moves for Cash from Investing Activities: up 510.15% in 2024, down 6481.11% in 2024.
  • Over 5 years, Cash from Investing Activities stood at -$2.1 million in 2021, then plunged by 4300.84% to -$92.0 million in 2022, then jumped by 169.84% to $64.3 million in 2023, then plunged by 178.82% to -$50.7 million in 2024, then jumped by 33.55% to -$33.7 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$33.7 million, $143.4 million, and $72.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Immatics 1.17 Bn 711.21 Mn - -9.48 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.48 Mn
Mar 31, 2026 -32.88 Mn
Dec 31, 2025 -33.66 Mn
Sep 30, 2025 143.39 Mn
Jun 30, 2025 72.73 Mn
Mar 31, 2025 49.24 Mn
Dec 31, 2024 -50.66 Mn
Sep 30, 2024 73.59 Mn
Jun 30, 2024 75.19 Mn
Mar 31, 2024 -262.70 Mn
Dec 31, 2023 64.27 Mn
Sep 30, 2023 -76.82 Mn
Jun 30, 2023 -18.33 Mn
Mar 31, 2023 -3.99 Mn
Dec 31, 2022 -92.03 Mn
Sep 30, 2022 -71.65 Mn
Jun 30, 2022 -58.01 Mn
Mar 31, 2022 6.55 Mn
Dec 31, 2021 -2.09 Mn
Sep 30, 2021 23.15 Mn